4.7 Review

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

期刊

BIOMOLECULES
卷 11, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/biom11081107

关键词

phytochemical; immune checkpoint; PD-1; PD-L1; cancer immunotherapy

资金

  1. Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea)
  2. Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C2037]
  3. National Cancer Center, Ministry of Health and Welfare, Republic of Korea [HA17C0037]

向作者/读者索取更多资源

The use of immune checkpoint inhibitors shows promise in cancer treatment but is hindered by severe immunogenic side effects and lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have the potential for cancer treatment. Studies have shown that some plant compounds can effectively modulate immune checkpoints in various cancers.
The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulating the immune system with ICIs still faces obstacles with severe immunogenic side effects and a lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have been applied for the treatment of multiple diseases, including cancer. Accumulated evidence provides the possibility of efficacy of phytochemicals in combinational with other therapeutic agents of ICIs, effectively modulating immune checkpoint-related signaling molecules. Recently, several phytochemicals have been reported to show the modulatory effects of immune checkpoints in various cancers in in vivo or in vitro models. This review summarizes druggable immune checkpoints and their regulatory factors. In addition, phytochemicals that are capable of suppressing PD-1/PD-L1 binding, the best-studied target of ICI therapy, were comprehensively summarized and classified according to chemical structure subgroups. It may help extend further research on phytochemicals as candidates of combinational adjuvants. Future clinical trials may validate the synergetic effects of preclinically investigated phytochemicals with ICI therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据